These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 28965854)

  • 1. Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer.
    Hoang B; Ernsting MJ; Tang WS; Bteich J; Undzys E; Kiyota T; Li SD
    Cancer Lett; 2017 Dec; 410():169-179. PubMed ID: 28965854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer.
    Hoang B; Ernsting MJ; Murakami M; Undzys E; Li SD
    Int J Pharm; 2014 Aug; 471(1-2):224-33. PubMed ID: 24853460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
    Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
    Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboxymethylcellulose-based and docetaxel-loaded nanoparticles circumvent P-glycoprotein-mediated multidrug resistance.
    Roy A; Murakami M; Ernsting MJ; Hoang B; Undzys E; Li SD
    Mol Pharm; 2014 Aug; 11(8):2592-9. PubMed ID: 24564177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
    Kosaka T; Hongo H; Oya M
    BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases.
    Ernsting MJ; Murakami M; Undzys E; Aman A; Press B; Li SD
    J Control Release; 2012 Sep; 162(3):575-81. PubMed ID: 22967490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using Flash Nanoprecipitation To Produce Highly Potent and Stable Cellax Nanoparticles from Amphiphilic Polymers Derived from Carboxymethyl Cellulose, Polyethylene Glycol, and Cabazitaxel.
    Bteich J; McManus SA; Ernsting MJ; Mohammed MZ; Prud'homme RK; Sokoll KK
    Mol Pharm; 2017 Nov; 14(11):3998-4007. PubMed ID: 28945432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.
    Terada N; Kamoto T; Tsukino H; Mukai S; Akamatsu S; Inoue T; Ogawa O; Narita S; Habuchi T; Yamashita S; Mitsuzuka K; Arai Y; Kandori S; Kojima T; Nishiyama H; Kawamura Y; Shimizu Y; Terachi T; Sugi M; Kinoshita H; Matsuda T; Yamada Y; Yamamoto S; Hirama H; Sugimoto M; Kakehi Y; Sakurai T; Tsuchiya N
    BMC Cancer; 2019 Feb; 19(1):156. PubMed ID: 30770773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
    Begemann D; Wang Y; Yang W; Kyprianou N
    Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle.
    Ernsting MJ; Hoang B; Lohse I; Undzys E; Cao P; Do T; Gill B; Pintilie M; Hedley D; Li SD
    J Control Release; 2015 May; 206():122-30. PubMed ID: 25804872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models.
    Ernsting MJ; Tang WL; MacCallum NW; Li SD
    Biomaterials; 2012 Feb; 33(5):1445-54. PubMed ID: 22079003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination Therapy of Metastatic Castration-Recurrent Prostate Cancer: Hyaluronic Acid Decorated, Cabazitaxel-Prodrug and Orlistat Co-Loaded Nano-System.
    Qu Z; Ren Y; Shen H; Wang H; Shi L; Tong D
    Drug Des Devel Ther; 2021; 15():3605-3616. PubMed ID: 34447241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic modification of carboxymethylcellulose and use thereof to prepare a nanoparticle forming conjugate of docetaxel for enhanced cytotoxicity against cancer cells.
    Ernsting MJ; Tang WL; MacCallum N; Li SD
    Bioconjug Chem; 2011 Dec; 22(12):2474-86. PubMed ID: 22014112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Update of a Carboxymethylcellulose-PEG Conjugate Platform for Delivery of Insoluble Cytotoxic Agents to Tumors.
    Yang Y; Bteich J; Li SD
    AAPS J; 2017 Mar; 19(2):386-396. PubMed ID: 27873118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening.
    Hongo H; Kosaka T; Suzuki Y; Oya M
    Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):59-66. PubMed ID: 34593983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer.
    Hongo H; Kosaka T; Oya M
    Cancer Sci; 2018 Sep; 109(9):2937-2945. PubMed ID: 29989268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.
    Francini E; Fiaschi AI; Petrioli R; Laera L; Bianco V; Ponchietti R; Roviello G
    Anticancer Drugs; 2015 Sep; 26(8):884-7. PubMed ID: 26053281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabazitaxel-loaded human serum albumin nanoparticles as a therapeutic agent against prostate cancer.
    Qu N; Lee RJ; Sun Y; Cai G; Wang J; Wang M; Lu J; Meng Q; Teng L; Wang D; Teng L
    Int J Nanomedicine; 2016; 11():3451-9. PubMed ID: 27555767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial.
    Kellokumpu-Lehtinen PL; Marttila T; Jekunen A; Hervonen P; Klintrup K; Kataja V; Utriainen T; Luukkaa M; Leskinen M; Pulkkanen K; Kautio AL; Huttunen T
    Anticancer Res; 2020 Dec; 40(12):6915-6921. PubMed ID: 33288585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.